Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity.
Charlotte Wilhelmina Wernberg, Vineesh Indira Chandran, Mette Munk Lauridsen...
https://pubmed.ncbi.nlm.nih.gov/40677693/Actively Recruiting
Led by Esbjerg Hospital - University Hospital of Southern Denmark · Updated on 2025-03-05
1200
Participants Needed
1
Research Sites
147 weeks
Total Duration
Researchers are studying the prognostic significance and prevalence of fatty liver disease NAFLD in patients with a body mass index BMI over 35. The study compares two groups those undergoing bariatric surgery and those with similar age, weight, and health conditions who choose not to have surgery. This non-randomized, prospective case-control study aims to better understand the effects of fatty liver disease in these patients over a long period. The intervention group includes 600 patients who will have bariatric surgery, specifically Roux-en-Y gastric bypass or gastric sleeve operations. The control group also includes 600 participants matched by age, BMI, and other health conditions but who do not undergo surgery. Both groups will be monitored over time to observe differences related to fatty liver disease and its progression. Participants will be followed for up to 10 years, with the main outcome being the number of deaths in each group during this period. Additional assessments include tracking the progression of fatty liver disease, changes in brain activity via EEG, intelligence quotient, and reaction times after surgery. Participants will provide consent and be monitored through clinical evaluations and tests over the follow-up period to gather comprehensive data on health outcomes.
CONDITIONS
Prognostic Significance of Fatty Liver Disease in Bariatric Patients
M
Mette M Lauridsen, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Esbjerg Hospital - University Hospital of Southern Denmark
Lead Sponsor
University of Southern Denmark
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Day of surgery
Participants undergo bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
1 visit (in-person)
Duration - Up to 24 months after surgery
Participants are monitored after surgery to assess recovery and changes in health.
Visits during follow-up assessments
Duration - Up to 10 years after inclusion
Participants are observed over a period of up to 10 years to track survival and progression of fatty liver disease.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Charlotte Wilhelmina Wernberg, Vineesh Indira Chandran, Mette Munk Lauridsen...
https://pubmed.ncbi.nlm.nih.gov/40677693/Esbjerg Hospital - University Hospital of Southern Denmark
Lead Sponsor
University of Southern Denmark
Collaborating Sponsor